A fixed-dose combination product primarily indicated for the management of capillary fragility and bleeding disorders. It combines a hemostatic agent (Adrenochrome Monosemicarbazone), a capillary stabilizer (Rutin), a synthetic vitamin K analogue (Menadione Sodium Bisulfite), and bone mineral components (Vitamin D and Calcium Phosphate). It is used to reduce bleeding time, strengthen capillary walls, and support coagulation, often in conditions like hemorrhagic diathesis, epistaxis, and menorrhagia.
Adult: One tablet twice or thrice daily, or as directed by the physician. Typically after meals.
Note: Administer orally with or after food to minimize gastric irritation and enhance absorption of fat-soluble components. Tablet should be swallowed whole with a full glass of water. Do not crush or chew.
Adrenochrome Monosemicarbazone stabilizes capillary endothelium and promotes platelet adhesion, reducing capillary permeability and bleeding time. Rutin (a bioflavonoid) exerts antioxidant and anti-inflammatory effects, reducing capillary fragility. Menadione Sodium Bisulfite is a water-soluble pro-vitamin K, serving as a precursor for the synthesis of active vitamin K-dependent clotting factors (II, VII, IX, X) in the liver. Vitamin D (Cholecalciferol) enhances intestinal absorption of calcium and phosphate. Calcium Phosphate provides elemental calcium and phosphate, essential for blood coagulation (as Factor IV), neuromuscular function, and bone mineralization.
Pregnancy: Category C: Use only if clearly needed. Safety not established. Menadione has been associated with kernicterus in newborns when used in high doses late in pregnancy. Benefit must outweigh risk.
Driving: Unlikely to affect driving ability. However, dizziness or flushing may occur rarely; caution advised if these symptoms are experienced.
| Warfarin and other Vitamin K Antagonists | Menadione can antagonize the anticoagulant effect, reducing INR. Risk of treatment failure. | Major |
| Thiazide Diuretics (e.g., Hydrochlorothiazide) | Reduce calcium excretion, increasing risk of hypercalcemia. | Moderate |
| Digoxin | Hypercalcemia can potentiate digoxin toxicity, leading to serious arrhythmias. | Major |
| Oral Tetracycline/Quinolone Antibiotics | Calcium can chelate these drugs, reducing their absorption. Administer at least 2-3 hours apart. | Moderate |
| Corticosteroids (e.g., Prednisolone) | Reduce calcium absorption and may antagonize vitamin D effect. | Moderate |
| Orlistat, Cholestyramine | Reduce absorption of fat-soluble vitamins (Vitamin D, Menadione). | Moderate |
| Phenytoin, Phenobarbital | Increase metabolism of Vitamin D, reducing its efficacy. | Moderate |